Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
S. Jost,Marie-Ann Kaldenbach,25 Autores,H. Dafsari
TLDR
Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used, but new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010, therefore, consensus proposals for updated LEDs are needed.
Resumo
To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.